Abstract 96P
Background
Flot (5-fluorouracil, leucovorin, oxaliplatin and docetaxel) is the standard regimen for perioperative chemotherapy in locally advanced gastric cancer. Preoperative chemotherapy downstages the tumor, increases pathological response. Patients receiving flot are hospitalised for more than a day. This study compares it with dox (docetaxel, oxaliplatin and capecitabine) - a daycare regimen, as capecitabine has already been proven non-inferior to 5-fluorouracil in advanced gastric cancer.
Methods
62 patients were enrolled in this prospective observational study. 31 patients received 4 doses of 2 weekly infusions of 5-fluorouracil- 2600 mg/m2, leucovorin - 200 mg/m2, oxaliplatin - 85 mg/m2, docetaxel- 50 mg/m2 on day 1. Rest 31 received 3 doses of 3 weekly infusions of docetaxel- 60 mg/m2, oxaliplatin - 130 mg/m2 on day 1 and tablet capecitabine -1000 mg/m2 bid for 14 days. Radiological response to chemotherapy were analysed 2 weeks after chemotherapy completion and categorised into stable disease, partial response, progressive disease and complete response according to recist criteria version 1.1. Chi-square test was applied for analysis.
Results
In flot arm, 38.1 % (8) had partial response, 66.7 % (12) had progressive disease, 55 % (11) had stable disease radiologically. In dox arm, 61.9 %(13) had partial response, 33.3 % (6) had progressive disease, 45 % (9) had stable disease radiologically . 3 patients in dox regimen did not have evaluation (1 lost to follow-up; 2 died during the course of treatment). P value obtained was 0.197. The radiological response to chemotherapy was not statistically significant between two groups.
Conclusions
The radiological response to chemotherapy post flot or dox regimen is not statistically different. Dox maybe considered as an alternative regimen to flot in neoadjuvant chemotherapy in locally advanced gastric cancer patients with the advantage being a daycare procedure, requiring less resources and manpower.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Economic evaluation of second-line treatment for patients with esophageal squamous cell carcinoma: A systematic review
Presenter: Gagandeep Kaur
Session: Poster viewing 02
110P - Neutrophil to lymphocyte ratio as a predictor of poor prognosis in advanced esophageal cancer
Presenter: Chaichana Chantharakhit
Session: Poster viewing 02
111P - Bicentric real-life analysis of the molecular portrait of patients with early onset metastatic biliary tract cancer
Presenter: Theresa Schmalfuss
Session: Poster viewing 02
112P - Prognostic role of sarcopenia before neoadjuvant chemoradiotherapy in patients with esophageal cancer: A retrospective study
Presenter: Mastaneh Sanei
Session: Poster viewing 02
113P - Brain metastases in esophageal cancer patients who have been treated with neoadjuvant immunotherapy plus chemotherapy: An inconsiderable complication
Presenter: Jun Liu
Session: Poster viewing 02
114P - Risk factors for oesophageal fistula: A life-threatening complication of treatment for oesophageal cancer
Presenter: Reo Omori
Session: Poster viewing 02
115P - Human epidermal growth factor receptor-2 (HER-2) expression status in patients with cholangiocarcinoma
Presenter: Thanit Imemkamon
Session: Poster viewing 02
116P - Spleen as an organ at risk (OAR) in adjuvant chemoradiotherapy of gastric cancer: Retrospective dosimetric single institutional experience
Presenter: Preethi Shetty
Session: Poster viewing 02
117P - Immunoprofile of adenosquamous carcinoma in gastric cancer
Presenter: Cheng-Han Wu
Session: Poster viewing 02
118P - Association between stomach cancer with behavioral and dietary factors: A case control study from Nepal
Presenter: Arun Shahi
Session: Poster viewing 02